share_log

Oppenheimer Downgrades Angion Biomedica to Perform From Outperform, Removes $8 Price Target

Oppenheimer Downgrades Angion Biomedica to Perform From Outperform, Removes $8 Price Target

奧本海默將Angion Biomedica的評級從跑贏大盤下調至表現,取消了8美元的目標股價
MT Newswires ·  2022/06/30 21:57

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論